QTTB - Q32 Bio Inc

QTTB - Q32 Bio Inc

https://www.q32bio.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Q32 Bio ( QTTB ) Q2 Loss Drops 45%

Motley Fool • 1 month, 1 week ago • score: -0.10

Q32 Bio ( NASDAQ:QTTB ) , a clinical-stage biotechnology company developing therapies for autoimmune and inflammatory diseases, released its second quarter results on August 6, 2025. The main news was a notably reduced GAAP net loss of $0.78 per share.

All You Need to Know About Q32 Bio ( QTTB ) Rating Upgrade to Buy

Zacks Commentary • 5 months ago • score: 0.31

Q32 Bio (QTTB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

None

52W High

$53.79

52W Low

$1.35

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

N/A

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

N/A

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

3.55

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

6.54%

Institutions (25–75% balanced)

69.54%

Shares Outstanding

12,197,600

Float

5,289,400

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

-14,662,000

Gross Profit (TTM)

-48,145,000

EPS (TTM)

-4.34

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-4.92%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

-0.0248

Previous

-0.0443

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025